pioglitazone has been researched along with Central Retinal Edema, Cystoid in 8 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the early association between pioglitazone and diabetic macular edema (DME)." | 7.79 | [Association between pioglitazone and diabetic macular edema]. ( Hoshikawa, Y; Ohkoshi, K, 2013) |
| "We report a case of severe diabetic macular edema (DME) that developed after pioglitazone was used by a patient with proliferative diabetic retinopathy." | 7.74 | Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. ( Asaumi, N; Kumagai, K; Mitamura, Y; Oshitari, T; Watanabe, M, 2008) |
| "To assess the early association between pioglitazone and diabetic macular edema (DME)." | 3.79 | [Association between pioglitazone and diabetic macular edema]. ( Hoshikawa, Y; Ohkoshi, K, 2013) |
| "We report a case of severe diabetic macular edema (DME) that developed after pioglitazone was used by a patient with proliferative diabetic retinopathy." | 3.74 | Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study. ( Asaumi, N; Kumagai, K; Mitamura, Y; Oshitari, T; Watanabe, M, 2008) |
| "Patients with type II diabetes mellitus were categorized into 2 groups depending on TZD intake." | 1.39 | Impact of thiazolidinediones on macular thickness and volume in diabetic eyes. ( Al Shaar, L; Azar, S; Bashshur, ZF; El-Mollayess, GM; Salti, HI, 2013) |
| ": The aim of the study was to verify if the analysis of a large spontaneous reporting database could generate early signals on these adverse drug reactions (ADRs) associated with TZDs." | 1.38 | Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. ( Biagi, C; Marchesini, G; Marra, A; Motola, D; Piccinni, C; Poluzzi, E; Raschi, E, 2012) |
| "We evaluated, in patients with type 2 diabetes (T2D), the short-term and long-term risks of developing DME among users vs nonusers of thiazolidinediones." | 1.38 | Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. ( Donnelly, R; Idris, I; Warren, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gokce, G | 1 |
| Durukan, AH | 1 |
| Erdurman, FC | 1 |
| Ceylan, OM | 1 |
| Sobaci, G | 1 |
| Hoshikawa, Y | 1 |
| Ohkoshi, K | 1 |
| Azar, S | 1 |
| El-Mollayess, GM | 1 |
| Al Shaar, L | 1 |
| Salti, HI | 1 |
| Bashshur, ZF | 1 |
| Fong, DS | 1 |
| Contreras, R | 1 |
| Oshitari, T | 1 |
| Asaumi, N | 1 |
| Watanabe, M | 1 |
| Kumagai, K | 1 |
| Mitamura, Y | 1 |
| Lambley, RG | 1 |
| Vahdani, K | 2 |
| Konstantinidis, A | 1 |
| Booth, A | 1 |
| Motola, D | 1 |
| Piccinni, C | 1 |
| Biagi, C | 1 |
| Raschi, E | 1 |
| Marra, A | 1 |
| Marchesini, G | 1 |
| Poluzzi, E | 1 |
| Idris, I | 1 |
| Warren, G | 1 |
| Donnelly, R | 1 |
8 other studies available for pioglitazone and Central Retinal Edema, Cystoid
| Article | Year |
|---|---|
Pioglitazone associated diabetic macular oedema.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetes Mellitus, Type 2; | 2012 |
[Association between pioglitazone and diabetic macular edema].
Topics: Adult; Aged; Aged, 80 and over; Diabetic Retinopathy; Female; Humans; Hypoglycemic Agents; Macular E | 2013 |
Impact of thiazolidinediones on macular thickness and volume in diabetic eyes.
Topics: Blood Glucose; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Gly | 2013 |
Glitazone use associated with diabetic macular edema.
Topics: Adult; Databases, Factual; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Glycated Hemoglobin; Hum | 2009 |
Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diuretics; Female; Fluorescein Angiography; | 2008 |
Rosiglitazone and pioglitazone. Beware macular oedema.
Topics: Diabetic Angiopathies; Diabetic Nephropathies; Heart Failure; Humans; Hypoglycemic Agents; Macular E | 2009 |
Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.
Topics: Adverse Drug Reaction Reporting Systems; Bone and Bones; Cardiovascular System; Clinical Trials as T | 2012 |
Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies | 2012 |